Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

NCT02601937 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT02601937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02601937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Lead sponsor
Epizyme, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 7, 2016
Completion date
October 22, 2021
Enrollment
109 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

ini1-negative tumors, malignant rhabdoid tumor of ovary, rhabdoid tumors, synovial sarcoma